查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1190712

電子醫學/生物電子醫學市場 - 增長、趨勢、COVID-19 影響和預測 (2023-2028)

Electroceuticals/Bioelectric Medicine Market- Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 116 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

電子醫療/生物電子醫療市場預計在預測期內 (2022-2027) 以 7.8% 的複合年增長率增長。

COVID-19 疫情對市場產生了重大影響。 高感染率和缺乏治療繼續困擾著許多國家，並使它們的經濟和衛生系統不堪重負。 在 COVID-19 流行期間，擇期手術已無限期推遲，以確保有能力處理急診病例並避免擇期手術患者暴露於 COVID-19。 此外，根據 2021 年 8 月發表的文章“COVID-19 大流行對希臘西北部心臟電子設備植入的影響”，冠狀病毒病 (COVID-19) 大流行影響了與心血管相關的醫院就診，並產生重大影響關於住院。 從頭移植和替代在第一個鎖定期間顯著下降，但在第二個鎖定期間沒有顯著變化。

在全球範圍內，慢性病患病率上升是推動市場發展的主要因素。 例如，根據世界衛生組織 (WHO) 2021 年 4 月的報告，非傳染性疾病 (NCDs)，也稱為慢性病，是影響遺傳、生理、環境和行為因素的長期疾病。它被認為是多種因素綜合作用的結果。 根據2021年7月發表的《印度人非傳染性疾病患病率為每千人116人：報告》一文，印度非傳染性疾病患病率為每千人11人，其中高血壓、胃腸道疾病和糖尿病居首位負擔。 此外，預計在預測期內，有神經和 CVD 疾病風險的老年人口增加將推動市場增長。

生物電子醫學用於治療多種疾病和病症，包括癌症、類風濕性關節炎、炎症性腸病、肥胖症、糖尿病、哮喘、癱瘓、失明、出血、缺血、器官移植、心髒病和神經退行性疾□□病。有望為疾病的診斷和治療帶來新的認識 基於過去十年的快速發展，該領域正在迅速擴大。 技術創新正在使設備變得更小、侵入性更小，並且在未來幾年內，公司將為市場帶來新的應用，例如周圍神經病變、關節炎、慢性阻塞性肺病、心力衰竭和 1 型糖尿病正在出現。

市場進入者也在開發生物電子醫學。 例如，GE Research 生物醫學團隊正在展示一種新型非侵入性方法，該方法使用超聲波來調節身體代謝和炎症控制系統的功能障礙。 生物電子醫學的研究傳統上依賴於植入式設備來刺激神經以達到治療效果。 GE 的一個研究團隊展示了使用無創超聲技術對目標器官內的神經功能進行直接和精確的刺激。 GE研究團隊的初步研究結果表明，需要對超聲用於周圍神經調節進行更多的投資和研究，需要超聲設備工程師和神經科學家之間的合作。表明有 因此，它顯示了生物醫藥市場的潛力和投資需求。

研究人員目前專注於開發各種基於生物電子學的治療設備，用於腫瘤刺激和神經調節。 這允許調節癌症信號通路，恢復健康的電脈沖模式，並預防癌症進展。 生物電醫學的最新進展可能被證明是一種比化療和手術更自然、更安全的癌症治療方法，後者有許多副作用。 目前，除了化療之外，電場療法還用於某些類型癌症的患者，以提高生存率和安全性。 例如，Bryne 等人表明，使用稱為“離子電滲療法”的低直流電場，可以迫使高濃度的局部藥物深入腫瘤。

另外，根據2020年12月發表的論文“Core Concept”，“生物電醫學的興起將引起研究人員、患者和產業界的興趣”，製藥行業也熱情高漲。 強生公司的產品組合目前包括多種生物電子設備。 這可能會在預測期內推動市場增長。

因此，上述因素預計將在預測期內推動市場增長。

主要市場趨勢

在電子醫學/生物電子醫學市場，心律失常領域有望佔據主要市場份額

預計在預測期內，心律失常部分將佔市場增長的主要市場份額。 根據 2021 年 2 月發表的題為“房顫全球流行病學”的文章，心律失常患病率上升是市場增長的主要驅動力。 日益嚴重的流行病和公共衛生挑戰”心房顫動是最常見的心律失常。 在全球範圍內，估計到 2050 年，美國將有 6-12 百萬人，到 2060 年歐洲將有 1790 萬人患有這種疾病。 心房顫動是缺血性中風的主要危險因素，並造成顯著的發病率和死亡率的顯著經濟負擔。 此外，根據美國國家慢性病預防中心 (CDC) 健康促進、心髒病和中風預防部 2021 年 9 月更新的事實，到 2030 年美國將有 1210 萬人患有心房顫動 (AFib)。估計的。 在美國，據說每年有超過 454,000 例以房顫為主要疾病的住院治療發生。

此外，除顫器和心臟起搏器等產品的廣泛接受也在推動市場增長。 此外，技術進步和產品批准的增加也推動了該細分市場的增長。 例如，2020 年 7 月，雅培公司的 Gallant 系列植入式心律轉復除顫器和採用藍牙技術的心臟再同步治療除顫器獲得了美國食品和藥物管理局的批准。 遠程數據跟蹤設備、安全磁共振成像 (MRI) 設備和數據記錄功能等先進起搏器技術能力推動了該領域的增長。

預計北美將佔據很大的市場份額，預計在預測期內也會如此。

COVID-19 在時間上與院外心臟驟停的增加有關。 根據 2021 年 5 月發表的文章“COVID-19 爆發期間的植入式心臟復律除顫器電擊”，紐約市、新奧爾良和波士頓在 COVID-19 高活動期間發生的除顫器電擊事件有所增加。 COVID-19 影響心血管系統，可導致心肌梗塞、血管內血栓形成和心律失常。 裝有植入式心律轉復除顫器 (ICD) 的人因心律失常而發生心臟驟停的風險增加。 ICD 休克率峰值似乎也與 COVID-19 峰值暫時相關。 然而，美敦力公佈的美國人口調查數據顯示，在 COVID-19 流行期間，慢性疼痛患者的生活有些艱難，慢性背痛目前呈上升趨勢。儘管 87% 的疼痛和腿痛患者表示他們的疼痛自兩年前的 2020 年 3 月流行病開始以來沒有改善或惡化，在 COVID-19 爆發期間沒有提供任何護理。被發現經歷了延遲 調查還顯示，絕大多數人希望有更多的治療選擇，但對脊髓刺激和靶向給藥選擇的認識仍然相對較低。 這是一個機會，可以讓患者了解減輕疼痛的所有可用選擇。

日益老齡化的人口、慢性病的流行以及對先進和高質量醫療保健的需求正在給醫療保健帶來巨大壓力，以跟上不斷增長的人口。 根據美國人口普查局的 2021 年老年人報告，目前美國有超過 5400 萬 65 歲及以上的成年人，約佔全國人口的 16.5%。 居住在美國的老年人口數量持續增長。 到 2050 年，65 歲及以上的成年人總數預計將增加到 8570 萬，約占美國總人口的 20%。

癌症、心血管疾病、糖尿病等傳染病和慢性病也在不斷增加。 據世界癌症觀察站（Globocan）2020年統計，2020年全球新增癌症患者人數為1930萬男性和女性，預計到2040年，男性和女性新增癌症患者人數將達到3020萬。 因此，這對於快速診斷和治療疾病的生物電子醫學市場來說是一個巨大的潛力。

此外，Biotronik 和 Medtronic 等歷史悠久的市場參與者的存在也推動了該地區的市場增長。 此外，有利的政府支持和區域產品批准也在推動市場增長。 例如，專注於治療慢性自身免疫性疾病患者的私人控股臨床階段生物電子醫療公司 Setpoint Medical 對多種生物製劑表現出不完全反應或不耐受。該公司已獲得美國藥物管理局的突破性設備指定用於類風濕性關節炎患者的新型生物電子設備。

競爭格局

電子醫學/生物電子醫學市場分散且競爭激烈，由幾家大型企業組成。 市場上的公司包括 SetPoint Medical、Sky Medical Technology、Cala Health、Boston Scientific Corporation、Abbott、Medtronic、Biotronik SE &Co.KG、Cochlear Ltd.、Sonova、LivaNova PLC、ElectroCore Inc、NeuroPace, Inc、Koninklijke Philips N.V.、NEVRO CORP., WEINMANN Emergency Medical Technology GmbH+Co.KG.

其他好處

  • Excel 格式的市場預測 (ME) 表
  • 三個月的分析師支持

內容

第1章介紹

  • 研究假設和市場定義
  • 調查範圍

第2章研究方法論

第 3 章執行摘要

第4章市場動態

  • 市場概覽
  • 市場驅動因素
    • 老年人口增加以及相關的神經和心血管疾病患病率增加
    • 技術進步
  • 市場製約因素
    • 電子醫療設備成本高
  • 波特的五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分（基於價值的市場規模：100 萬美元）

  • 按設備類型
    • 植入式電療設備
    • 無創電療儀
  • 按產品分類
    • 除顫器
    • 起搏器
    • 刺激器
    • 其他
  • 通過申請
    • 心律失常
    • 疼痛管理
    • 帕金森病
    • 抑鬱症
    • 其他
  • 最終用戶
    • 醫院
    • 診所
    • 其他
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東和非洲
      • 海灣合作委員會
      • 南非
      • 其他中東和非洲地區
    • 南美洲地區
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章競爭格局

  • 公司簡介
    • SetPoint Medical
    • Sky Medical Technology
    • Cala Health
    • Boston Scientific Corporation
    • Abbott Laboratories
    • Medtronic
    • Biotronik SE & Co. KG
    • Cochlear Ltd.
    • Sonova
    • LivaNova PLC.
    • ElectroCore Inc.
    • NeuroPace, Inc.
    • Koninklijke Philips N.V.
    • NEVRO CORP.
    • WEINMANN Emergency Medical Technology GmbH+Co. KG

第7章 市場機會與今後動向

簡介目錄
Product Code: 91075

The electroceuticals/bioelectric medicine market is projected to register a CAGR of 7.8% during the forecast period (2022-2027).

The COVID-19 epidemic has had a significant impact on the market. Due to the high rate of infection and the lack of treatment, many countries were suffering and continue to burden their economies and health care systems. Elective procedures have been postponed indefinitely during the COVID-19 pandemic to provide capacity to deal with the emergency caseload and avoid exposing elective patients to COVID-19. Also, as per the article published in August 2021 titled "Impact of COVID-19 pandemic on cardiac electronic device implantations in Northwestern Greece", The coronavirus disease (COVID-19) pandemic seems to have a significant impact on cardiovascular-related hospital visits and admissions. During the first lockdown period, both de novo implantations and replacements decreased significantly, while there was no significant change during the second lockdown period.

Globally, the rising prevalence of chronic disorders is a major factor driving the market forward. For instance, as per the April 2021 report of the World Health Organization (WHO), non-communicable diseases (NCDs), also known as chronic diseases, are long-duration diseases and are the result of a combination of genetic, physiological, environmental, and behavioral factor. According to the article titled ' Prevalence of Non-Communicable Diseases Among Indiands is 116 per 1,000 : Report' published in July 2021 Prevalence of non-communicable diseases in India is 11 per 1,000 population with hypertension, digestive diseases and diabetes leading the burden. Additionally, an increase in the geriatric population at risk of neurological and CVD diseases is expected to fuel market growth over the forecast period.

Bioelectronic Medicine promises to bring new insights into diagnosing and treating diseases and conditions as varied as cancer, rheumatoid arthritis, inflammatory bowel disease, obesity, diabetes, asthma, paralysis, blindness, bleeding, ischemia, and organ transplantation, cardiovascular disease, neurodegenerative diseases, and others. Building on a surge of progress in the past decade, the field is rapidly expanding. Technical innovations are making devices smaller and less invasive, with companies bringing new applications to market in the next several years, including for peripheral neuropathy, arthritis, chronic obstructive pulmonary disease, heart failure, and Type 1 diabetes.

Bioelectric Medicine is being developed by market participants as well. For example, GE Research's bioelectronic medicine team is using ultrasound to demonstrate potentially groundbreaking non-invasive methods to regulate dysfunction in the body's metabolic or inflammatory control systems. Bioelectronic medicine research traditionally relied on implanted devices to stimulate nerves and achieve therapeutic results. The GE Research team demonstrates the precise stimulation of nerve features directly within target organs using a non-invasive ultrasound technique. The preliminary findings of the GE Research team indicate that more investment and research into the use of ultrasound for peripheral neuromodulation is warranted and that increased collaboration between ultrasound device engineers and neuroscientists will be required. Hence, showing potential and simultaneously the need for investment in the biomedicine market.

Researchers are now looking into developing various bioelectronics-based therapeutic devices for tumor stimulation and neural modulation. This allows for the control of cancer signaling pathways, the restoration of healthy electrical impulse patterns, and the prevention of cancer progression. Recent advancements in bioelectric Medicine may prove to be a more natural and safe approach to cancer treatment than chemotherapy and surgery, both of which have numerous side effects. In today's world, patients with certain types of cancer are given electric field therapies in addition to chemotherapy to improve survival and safety. For instance, Bryne et al. showed that a high concentration of localized drugs could be forced deep inside the tumors using low direct current electric fields, referred to as "iontophoretic chemotherapy".

Also," per the article published in December 2020, "Core Concept: The rise of bioelectric medicine sparks interest among researchers, patients, and industry," the ph,"maceutical industry is also on board. Johnson & Johnson's portfolio now includes several bioelectronic devices. This is likely to boost the market growth over the forecast period.

Thus the above mentioned factors are expected to drive the growth of the market during the forecast period.

Key Market Trends

The Arrhythmia Segment is Expected to Hold a Major Market Share in the Electroceuticals/Bioelectric Medicine Market

The Arrhythmia segment is expected to hold a major market share in the growth of the market during the forecast period. The rising prevalence of arrhythmia is the major factor driving market growth as per the article published in February 2021 titled "Global Epidemiology of Atrial Fibrillation: An Increasing Epidemic and Public Health Challenge," Atrial fibrillation is the most frequent cardiac arrhythmia. It has been estimated that 6-12 million people worldwide will suffer from this condition in United States by 2050 and 17.9 million people in Europe by 2060. Atrial fibrillation is a major risk factor for ischemic stroke and provokes an important economic burden along with significant morbidity and mortality. Also, according to the National Center for Chronic Disease Prevention (CDC) and Health Promotion, Division for Heart Disease and Stroke Prevention facts updated on September 2021, it is estimated that 12.1 million people in United States will have Atrial fibrillation (AFib) in 2030. According to the same source, more than 454,000 hospitalizations with AFib as the primary diagnosis happen yearly in United States.

Furthermore, the products such as defibrillators and pacemakers are widely accepted by the population, which is also boosting the market growth. Additionally, growing technological advances and product approvals drive segment growth. For example, in July 2020, Abbott Laboratories received approval from United States Food and Drug Administration for its Gallant line, which includes an implanted cardioverter-defibrillator and a cardiac resynchronization therapy defibrillator with Bluetooth technology. Advance pacemaker technology features such as remote data tracking devices, secure magnetic resonance imaging (MRI) devices, and data recording functionality enhance segment growth.

North America is Expected to Hold a significant share in the market and is expected to do the Same in the Forecast Period.

COVID-19 was temporally associated with an increase in out-of-hospital cardiac arrests. As per the article published in May 2021 on "Implantable Cardioverter-Defibrillator Shocks During COVID-19 Outbreak", Defibrillator shock episodes increased during the higher COVID-19 activity in New York City, New Orleans, and Boston. COVID-19 can affect the cardiovascular system, resulting in myocardial injury, intravascular thrombosis and arrhythmias. Individuals with an implantable cardioverter-defibrillator (ICD) are at increased risk for arrhythmic sudden cardiac arrest. Spikes in ICD shock rates also appeared to be temporally associated with the COVID-19 surge. However, the data released from Medtronic's survey on United States population demonstrating several struggles for those with chronic pain during the COVID-19 pandemic found that 44% of current chronic back and leg pain sufferers experienced care delays during the COVID-19 pandemic despite 87% reporting that their pain has not improved - or has even worsened since the pandemic began two years ago in March 2020. The survey also demonstrated that an overwhelming majority want more treatment options, yet awareness of spinal cord stimulation and targeted drug delivery options remains relatively low. That represents an opportunity to educate patients about the full range of options available to help alleviate their pain.

The rising geriatric population, increasing prevalence of chronic diseases, and demand for advanced quality healthcare are putting immense pressure on healthcare to meet the population's increasing demand. As per United States Census Bureau's 2021 senior report, More than 54 million adults ages 65 and older live in United States today, accounting for about 16.5% of the nation's population. The number of older adults living in United States is growing. By 2050, the total number of adults ages 65 and older is projected to rise to 85.7 million, roughly 20% of the overall United States population.

There is an increasing prevalence of infectious and chronic diseases such as cancer, cardiovascular, diabetes, and many more. According to the Global Cancer Observatory (Globocan) Statistics 2020, there were 19.3 million new cases of cancer all over the world, accounting for both sexes in 2020, and the same source reported that the incidence of cancer was growing at a rapid pace in the world and estimated that the number of new cases of cancer in both sexes will reach to 30.2 million by 2040. Hence, this is huge potential for the bioelectric medicine market to quickly diagnose and treat diseases.

Furthermore, the presence of well-established market players such as Biotronik and Medtronic is also supporting the market growth in the region. Besides, favorable government support and regional product approvals also drive market growth. For instance, SetPoint Medical, a privately held clinical-stage bioelectronic medicine company dedicated to treating patients with chronic autoimmune diseases, has got a Breakthrough Device Designation from United States and Drug Administration for the use of its novel bioelectronic device for patients with rheumatoid arthritis who have an incomplete response to or are intolerant to multiple biologic drugs.

Competitive Landscape

The electroceuticals/bioelectric medicine market is fragmented and competitive and consists of several major players. Some of the players operating in the market are SetPoint Medical, Sky Medical Technology, Cala Health, Boston Scientific Corporation, Abbott, Medtronic, Biotronik SE & Co. KG, Cochlear Ltd., Sonova, LivaNova PLC., ElectroCore Inc., NeuroPace, Inc., Koninklijke Philips N.V., NEVRO CORP., and WEINMANN Emergency Medical Technology GmbH + Co. KG.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Geriatric Population and Subsequent Growth in the Prevalence of Neurological & Cardiovascular Disorders
    • 4.2.2 Technological Advancements
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Electroceutical Devices
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Device Type
    • 5.1.1 Implantable Electroceutical Devices
    • 5.1.2 Non-invasive Electroceutical Devices
  • 5.2 By Product
    • 5.2.1 Defibrillators
    • 5.2.2 Pacemakers
    • 5.2.3 Stimulators
    • 5.2.4 Others
  • 5.3 By Application
    • 5.3.1 Arrhythmia
    • 5.3.2 Pain Management
    • 5.3.3 Parkinson's Disease
    • 5.3.4 Depression
    • 5.3.5 Others
  • 5.4 End User
    • 5.4.1 Hospitals
    • 5.4.2 Clinics
    • 5.4.3 Others
  • 5.5 Geography
    • 5.5.1 North America
      • 5.5.1.1 United States
      • 5.5.1.2 Canada
      • 5.5.1.3 Mexico
    • 5.5.2 Europe
      • 5.5.2.1 Germany
      • 5.5.2.2 United Kingdom
      • 5.5.2.3 France
      • 5.5.2.4 Italy
      • 5.5.2.5 Spain
      • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
      • 5.5.3.1 China
      • 5.5.3.2 Japan
      • 5.5.3.3 India
      • 5.5.3.4 Australia
      • 5.5.3.5 South Korea
      • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle-East and Africa
      • 5.5.4.1 GCC
      • 5.5.4.2 South Africa
      • 5.5.4.3 Rest of Middle-East and Africa
    • 5.5.5 South America
      • 5.5.5.1 Brazil
      • 5.5.5.2 Argentina
      • 5.5.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 SetPoint Medical
    • 6.1.2 Sky Medical Technology
    • 6.1.3 Cala Health
    • 6.1.4 Boston Scientific Corporation
    • 6.1.5 Abbott Laboratories
    • 6.1.6 Medtronic
    • 6.1.7 Biotronik SE & Co. KG
    • 6.1.8 Cochlear Ltd.
    • 6.1.9 Sonova
    • 6.1.10 LivaNova PLC.
    • 6.1.11 ElectroCore Inc.
    • 6.1.12 NeuroPace, Inc.
    • 6.1.13 Koninklijke Philips N.V.
    • 6.1.14 NEVRO CORP.
    • 6.1.15 WEINMANN Emergency Medical Technology GmbH + Co. KG

7 MARKET OPPORTUNITIES AND FUTURE TRENDS